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Abstract
The purpose of this editorial is to provide a brief history of National Institutes of Health National Cancer Institute (NCI)
workshops as related to quantitative imaging within the oncology setting. The editorial will then focus on the recently
supported NCI initiatives, including the Quantitative Imaging Network (QIN) initiative and its organizational structure,
including planned research goals and deliverables. The publications in this issue of Translational Oncology come from
many of the current members of this QIN research network.
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Discussion
The National Cancer Institute (NCI; Bethesda, MD) has been active
in supporting quantitative imaging (QI) for the last decade, within
the context of cancer screening, prediction and measurement of
response to therapy. This has included the organization and comple-
tion of several targeted workshops for the last decade related to this
topic and support for a number of related research initiatives. The
workshop topics and recommendations will first be briefly reviewed
as they provide the context by how NCI leadership justified the
support for the research initiatives. Several of the NCI initiatives
and progress made will first be reviewed briefly, followed by a more
extensive discussion of the Quantitative Imaging Network (QIN),
the topic of this issue of Translational Oncology. The intent of this
editorial is thus to clarify historically how NCI has developed ini-
tiatives to support QI and the QIN and to outline our continued
commitment to support this important area research.
Several trans-NIH workshops were organized where NCI had an
important role. The first such workshop was organized in June 2004
under two National Institutes of Health (NIH)-wide consortiums,
namely, the Bioengineering Consortium [1] and the NIH BECON
BISTIC Symposium 2004 [2]. It was entitled “Biomedical Infor-
matics for Clinical Decision Support: A Vision for the 21st Century”
and highlighted the need for the development of QI methods, within
the broader context of clinical data collection strategies, and harmo-
nization of data acquisition and processing across imaging and other
biosensors. The primary recommendation made as a result of this
workshop was the critical need for improved data integration methods
from data collected by these diverse platforms, as required to support
the robust implementation of clinical decision support software tools
in the clinical trial setting, namely, for cancer and other diseases. Re-
commendations were also made to develop public research resources
to promote the development and validation of clinical decision sup-
port tools. NIH BECON BISTIC has greatly expanded its role for
the last decade, particularly in the area of informatics requirements
for genomics, as well as modeling and analysis more generally. Now,
NIH BECON BISTIC is collaborating with the newly formed NIH
Big Data to Knowledge Initiative, which includes data collection by
QI [3]. Already a new NIH initiative has been announced, and there
are plans for small grants (R01s) that are to be funded in targeted big
data areas as well.
The second complementary workshop was organized in 2006 by
National Institute of Standards and Technology, NCI, and other
NIH institutes, in collaboration with the US Food and Drug Admin-
istration, as it became increasingly clear that technical standards for
QI were required [4]. The intended goal of this transfederal agency
imaging workshop was to engage all stakeholders including aca-
demia, the device and pharmaceutical industries, and imaging soci-
eties such as the Radiological Society of North America (RSNA),
Society of Nuclear Medicine, the American Association of Physicists
in Medicine, and International Society of Magnetic Resonance in
Medicine to recognize the need for QI standards and to play key
roles in promoting and adopting these standards within the clinical
Address all correspondence to: Laurence P. Clarke, PhD, Suite 6066, EPN 6130
Executive Blvd, Bethesda, MD 20892. E-mail: lclarke@mail.nih.gov
Received 12 December 2013; Revised 14 January 2014; Accepted 15 January 2014
Copyright © 2014 Neoplasia Press, Inc. All rights reserved 1944-7124/14/$25.00
DOI 10.1593/tlo.13832
www.transonc.com
Trans la t iona l Onco logy Volume 7 Number 1 February 2014 pp. 1–4 1
trial setting. The National Institute of Standards and Technology
workshop recommendations had an impact on the formulation of
national consensus approaches as applied to QI methods for cancer,
Alzheimer’s disease, and osteoporosis in particular. One important
outcome, in part, was the formation of a unique alliance organized
by the RSNA referred to as the “Quantitative Imaging Biomarker
Alliance” initiated in 2007 and later supported by National Institute
of Biomedical Imaging and Bioengineering that focuses on current
QI methodology in clinical trials [5]. Another outcome, in part, was
an increased interest in the formation of Public-Private Partnerships
with the pharmaceutical industries, namely, as important stake-
holders, to promote standardized QI protocols for drug trials by
the congressionally mandated Foundation of the NIH, partnering
with NCI and other NIH institutes [6].
NCI has organized several other workshops specifically dedicated
to the role of QI as applied to the cancer problem. For example, NCI
in collaboration with Canadian Institute of Health Research, Insti-
tute of Cancer Research and Cancer Research United Kingdom
held a workshop in London (June 2011) entitled “Linking ’Omics
to Patient Care Through Imaging” [7]. One of the primary goals
of this meeting was to explore the importance of correlation of quan-
titative imaging methods with the emerging field of genomics for
clinical decision support and to explore leveraging of research re-
sources by the different cancer funding agencies on an international
scale. This workshop resulted in expanding the support for QIN
teams by CIHR for Canadian investigators, with ongoing discussions
with Cancer Research United Kingdom and other international con-
tacts in India and China to explore further leveraging of research
resources including imaging archives. Finally, NCI organized a
workshop in June 2013 entitled “Correlating Imaging Phenotypes
with Genomic Signatures” where one of the goals was to explore
how to scale up research resources and high-speed computation
methods, including cloud computing, to correlate imaging pheno-
types with genomics signatures across large-scale studies to predict
the response to drug or radiation therapy. The recommendations in-
cluded the need for further technical standards for QI to implement
these proposed correlation studies, including the expansion of
research sources, such as The Cancer Imaging Archive (TCIA) [8],
designed to permit correlation of imaging phenotypes with genomic
data collected by The Cancer Genome Atlas Initiative [9]. Thus, all
the above workshops have, in part, laid the foundation for NCI lead-
ership to not only identify a means to address potential solutions for
QI standards as applied to cancer but more importantly to assist in
justifying support for QI initiatives.
The first NCI QI initiatives were focused on the development of
public resources such as annotated image databases for the purpose of
permitting the comparison of the relative performance of algorithms
for cancer detection or measurement of response to therapy, referred
to as the “Lung Image Data Base Consortium” (2002-2007) [10]
and the “Reference Image Database to Evaluate Response to Therapy”
(2005-2010) [11]. Both these databases were originally hosted by
the NCI Biomedical Imaging Archive, developed in 2006 under the
NCI Biomedical Informatics Grid (caBIG) initiative. More recently,
they have been hosted on TCIA, starting in 2009, to ensure Health
Insurance Portability and Accountability Act (HIPAA) compliance
[8]. Although the Lung Image Data Base Consortium and Reference
Image Database to Evaluate Response to Therapy databases helped to
develop consensus on methods for evaluation of algorithms and to
promote the importance of public research resources in QI, they did
not address issues related to implementation of QI protocols within
the clinical trial setting. This limitation lead to another NCI initiative
in 2005 designed to support “Clinical Centers of Excellence in QI”
across several NCI-designated cancer centers, referred to as the Imaging
Response Assessment Teams (IRATs) [12]. This initiative resulted in
the formation of several multidisciplinary IRAT programs/cores within
NCI-designated cancer centers. These cores have succeeded in imple-
menting several improvements in clinical trial design in collaboration
with several NCI clinical trial networks.
A complementary initiative, referred to as the Centers for Quantitative
Imaging Excellence, was initiated in 2009, with the goal of certification
of NCI-designated cancer centers for QI methods in collaboration with
American College of Radiology Imaging Network (ACRIN; 2010-2013)
[13]. Yet despite the level of success by the IRAT and Centers for
Quantitative Imaging Excellence initiatives, it became increasingly clear
that NCI needed to support the development and evaluation of the
next generation of advanced image acquisition and analysis methods
while promoting in parallel the development of technical imaging stan-
dards and expanded research resources. Thus, this sequence of workshops
and initiatives played an important role in justifying NCI investment
in supporting the QIN, approved in 2007, published in 2008 [14],
and renewed in 2011 [15]. A reissue of the program announcement
has been approved forMay 2014 for an additional three years, on the basis
of the success of the earlier initiatives, and now includes support for
Trans-QIN research infrastructure.
The QIN PAR-11-150 is a cooperative agreement using a U01
funding mechanism. The primary goals of QIN are as follows: 1)
the collection of image and metadata from ongoing phases 1 to 3
clinical trials to generate a research resource of relevant clinical data,
2) development of innovative methods for data collection and anal-
ysis using this research resource, and 3) exploration of a means to
develop a consensus on QI methods, with a long-term goal of
validating the performance of clinical decision support systems for
imaging, within the clinical trial setting. The technical and clinical
focus of QIN is to develop robust methods to predict and/or measure
response to therapy and encourage their broad dissemination within
the imaging, oncology, and device industry communities. These goals
are consistent with the increasing interest by NCI in the implement-
ing of adaptive therapy trials and personalized or precision medicine
therapy strategies that will require advanced molecular and functional
imaging methods. Applications to the QIN initiative thus require
multidisciplinary teams of researchers to be developed across both
cancer and computer science centers of excellence to address all of
the resources necessary to meet these goals. The public announcement
(PAR) requires oncologists, radiologists, medical physicists, computer
scientists, and informatics, who traditionally often do not collaborate
together on a large scale, to participate in each research team. NCI
now has 17 participating multidisciplinary teams in the network,
comprising more than 200 funded investigators, with two additional
teams funded in the last quarter of 2013 and will join the network
early in 2014. Most of the teams are located within NCI-designated
comprehensive cancer centers where there is an opportunity to explore
common research cores and/or research resources.
The QIN has a unique network management structure as shown
in Figure 1. It is specifically designed to encourage research collabo-
ration across cancer center sites and other centers of excellence. The
governance consists of 1) an overarching Executive Committee that
coordinates the research goals within the network and as an outreach
effort to interact with other imaging stakeholders and 2) a Coordinating
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Committee that manages four cross-team working groups (WGs)
shown in Figure 1. The WGs are tasked to develop consensus posi-
tions, namely, on the following: 1) Data Acquisition, 2) Bioinformatics/
Information Technology (IT) and Data Sharing, 3) Image Analysis
and Performance Metrics, and 4) Clinical Trial Design and Devel-
opment. The timetable and growth of the QIN-funded teams since
2009 is shown in Figure 2, where the necessary population of WGs
was only met in late 2011, namely, to develop consensus approaches
across several imaging modalities and organ sites.
This special issue of Translational Oncology contains articles of
research progress by several different QIN research teams and WGs.
The research efforts by these investigators are to be highly commended
as they have enthusiastically accepted the task to meet the goals of
this network, as reflected in the wide range of publications in this issue
of the journal. For example, significant advances have been made in
phantom designs that address the physical measurement uncertainty
problem across different sites for a given imaging platform, such as
positron emission tomography-computed tomography (PET-CT),
diffusion-weighted–magnetic resonance imaging (DW-MRI), and
dynamic contrast-enhanced–magnetic resonance imaging (DCE-MRI).
This work has led to exploring a means for harmonizing data collection
across these imaging platforms by modeling and characterization of
data collection across platforms, in particular PET CT and DW MRI.
Another example is the development of a range of advanced software
tools that have the potential to both operate across different clinical sites
for a given imaging platform and minimize operator or imaging site de-
pendence on data collection and analysis. The latter goals are critical to
support multisite, multiplatform clinical trials and acceptance by oncol-
ogists involved in cancer therapy trials. Similarly, the informatics and
metrology tools required to compare the relative performance of algo-
rithms in an objective manner, commonly referred to as “Grand Chal-
lenges,” have been developed and initiated for CT, DCE, and DW
MRI, where the latter methods proved to be technically very challeng-
ing. A means for sharing annotated data and metadata has been imple-
mented with patient data deidentification methods meeting HIPAA
requirements using the TCIA [16], a critical requirement for a public
resource. Initial efforts for software tool sharing, particularity metrology
tools, are being explored, for example, using HUBzero (http://hubzero.
org/about; Purdue University, West Lafayette, IN) [17]. Plans are in
progress to make this data and metrology tools both publically available
once themethods are fully validated by theQINnetwork andworkwith
RSNA (Quantitative Imaging Biomarker Alliance) and other inter-
actional groups to seek further optimization of QI methods for cancer
and other diseases.
The QIN clinical trial design and development WG has been also
actively collaborating for the last year with the Eastern Cooperative
Oncology Group (ECOG)-ACRIN and Cancer and Leukemia Group
B-Alliance for Clinical Trials in Oncology (CALGB-Alliance) both
groups involved in the recently formed NCI National Clinical Trial
Network [18]. These developments are consistent with the long-term
goal for QIN to serve as cost-effective technical research resource for
oncology trials both nationally and internationally and to develop highly
reproducible QI techniques that provide greater biologic meaning to
clinical trial end points [19]. The above collaboration has also included
the use of advanced molecular imaging methods, such as novel QI
tracers with (18F) fluorothymidine for PET scanning or QI techniques
with conventional imaging modalities using contrast-enhanced CT [20].
The NCI long-term strategy for support of QI has been through
the use of a series of U01 and R01 program announcements (PARs)
that permit the enrichment of the NCI imaging portfolio. One
aspect of this strategy is the implementation of a hub and spoke
model, where the QIN U01 serves as the hub or test bed for evalu-
ation of QI methods. Examples include PARs such as the Academic
Industry Partnerships (PAR-13-169, R01) for translation technology
development [21], where such six R01s that are using QIN as a test
bed have been supported. Another example is a Trans-NCI PAR
(R01, U01, and U24s) for informatics that includes imaging, with
one U24 funded, again using QIN as a test bed [22]. Investigators
throughout the imaging research community, both nationally and
internationally, are thus highly encouraged to seek support for QI
methods through these PARs and planned NIH Big Data Initiatives
and should make contact with NCI program staff for advice on sub-
mission of cancer-related applications for support.
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